ipilimumab,nivolumab
bms
['nivo', 'ipilimumab', 'nivolumab', '9la', 'lung', 'yervoy', 'opdivo', '$bmy']
three-year data from phase 3 #checkmate9la trial demonstrate long-term, durable survival outcomes of #opdivo (#nivolumab) plus #yervoy (#ipilimumab) with two cycles of chemotherapy for patients with metastatic #nonsmallcelllungcancer #asco22 $bmy 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.